Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HanchorBioTPE:7827 -0.32%9 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates TPE:7827 with a GF Score™ of 9/100. Among 954 Biotechnology companies, HanchorBio ranks worse than 57.55% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. HanchorBio's Free Cash Flow for the
three
months ended in Mar. 2026 was NT$-229.3 Mil. HanchorBio's Revenue for the
three
months ended in Mar. 2026 was NT$0.0 Mil. Therefore, HanchorBio's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical data trend for HanchorBio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:7827 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, HanchorBio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HanchorBio FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HanchorBio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where HanchorBio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HanchorBio (TPE:7827) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HanchorBio and its competitors. According to the industry distribution chart, HanchorBio ranks #549 out of 954 companies in the Biotechnology industry, placing it in the top 57.5%.
Is HanchorBio's FCF Margin % too high?
HanchorBio's current FCF Margin % is 0.00%. Based on the distribution chart, HanchorBio ranks #549 out of 954 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HanchorBio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does HanchorBio's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HanchorBio ranks #549 out of 954 companies for FCF Margin %. This places HanchorBio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HanchorBio and its competitors. HanchorBio's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HanchorBio stock overvalued right now?
HanchorBio (TPE:7827) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. HanchorBio's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For HanchorBio (TPE:7827), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HanchorBio Inc through its subsidiaries, is conducting research and development of new anti-cancer drugs, utilizing an Fc-based biopharmaceutical platform technology to reactivate the immune system in the fight against disease. The core technology of HanchorBio is the FBDB (Fc-Based Designer Biologics) platform, which focuses on the development of next-generation immuno-oncology fusion protein therapeutics. This platform utilizes the antibody Fc region as a backbone, onto which various engineered anti-cancer molecules are constructed through protein engineering. Combined with AI-assisted drug design capabilities, this technology is dedicated to overcoming key challenges in tumor immunotherapy.
9GF Score
Get the complete analysis for TPE:7827
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7827 has been successfully added to your 
